Nasdaq · Biotech stocks database
EXEL (Exelixis Inc.) stock: $58.36, $14.46B market cap, $777.2M cash, $13.68B EV, $16.43B fully diluted market cap. Next expected readout: Nov-26. Lead program: XL092 (Non-Clear Cell Renal Cell Carcinoma), Phase 3. Data from Fully Diluted's biotech stocks database.
| Cash | $777.2M |
|---|---|
| Debt | $0.0M |
| Net cash | $777.2M |
| Enterprise value | $13,683.3M |
| Basic shares | 248.9M shares |
| Fully diluted shares | 281.5M shares |
| Fully diluted market cap | $16,427.3M |
| Cash per share | $3.12 |
Cash figures as of 2026-04-03. Database snapshot: 2026-09-21.
Loading EXEL daily closes…
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|---|---|---|---|
| Oct 12 - Nov 23 | XL092 | Phase 1 | Neoplasm Malignant; Renal Cell Carcinoma; Hormone Receptor Positive Breast Carcinoma | — |
| Nov 23, 2026 - Jan 4, 2027 | Cabozantinib | Phase 2 | Castration-resistant Prostate Cancer; Metastatic Cancer | — |
| Jan 4 - Feb 15 | XB010 | Phase 1 | Locally Advanced or Metastatic Solid Tumors; Esophageal Squamous Cell Cancer; Head and Neck Squamous Cell Cancer | — |
| Jan 26 - Mar 9 | XL092 | Phase 3 | Non-Clear Cell Renal Cell Carcinoma | — |
| Jan 31 - Mar 14 | Cabozantinib | Phase 2 | Papillary Renal Cell Carcinoma; Unclassified Renal Cell Carcinoma; Translocation Renal Cell Carcinoma | — |
| Mar 14 - Apr 25 | Zanzalintinib | Phase 1 | Renal Cell Carcinoma (RCC); Metastatic Castration-Resistant Prostate Cancer (mCRPC); Urothelial Carcinoma (UC) | — |
| Jul 12 - Aug 23 | XB628 | Phase 1 | Solid Tumor; Advanced Solid Tumor; Metastatic Solid Tumor | — |
| Dec 13, 2027 - Jan 24, 2028 | XB371 | Phase 1 | Solid Tumors | — |
| Apr 11 - May 23 | Zanzalintinib | Phase 2 | Meningioma | — |
| Sep 11 - Oct 23 | Zanzalintinib | Phase 1 | Cancer; Pediatric Cancer | — |
| Sep 12 - Oct 24 | Zanzalintinib | Phase 3 | Head and Neck Squamous Cell Carcinoma | — |
| Feb 14 - Mar 28 | XL309 | Phase 1 | Advanced Solid Tumor | — |
| Jun 11 - Jul 23 | Zanzalintinib | Phase 2 | Clear Cell Renal Cell Cancer (ccRCC); Clear Cell Renal Carcinoma; Clear Cell Renal Cell Carcinoma Metastatic | — |
| Aug 11 - Sep 22 | Zanzalintinib | Phase 3 | Pancreatic Neuroendocrine Tumor (pNET); Extra-Pancreatic Neuroendocrine Tumor (epNET) | — |
| May 17 - Jun 28 | Zanzalintinib | Phase 3 | Colorectal Cancer | — |
| Jul 12 - Aug 23 | Cabozantinib | Phase 3 | Cancer; Renal Cell Carcinoma (RCC); Pancreatic Neuroendocrine Tumors (pNET) | — |
| Jan 8 - Feb 19 | Belzutifan | Phase 3 | Carcinoma, Renal Cell | — |
| Dec 7, 2031 - Jan 18, 2032 | Belzutifan | Phase 2 | Renal Cell Carcinoma | — |
| Apr 9 - May 21 | Belzutifan | Phase 3 | Renal Cell Carcinoma | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.